| Literature DB >> 35158870 |
Tamara V Azizova1, Evgeny V Bragin1, Maria V Bannikova1, Nobuyuki Hamada2, Evgeniya S Grigoryeva1.
Abstract
Secondary glaucoma is a typical normal tissue complication following radiation therapy involving ocular radiation exposure at high fractionated dose (several tens of Gy). In contrast, recent studies in acutely exposed Japanese atomic bomb survivors showed a significantly increased risk for normal-tension glaucoma (NTG, a subtype of primary open-angle glaucoma) at much lower dose, but such information is not available in any other cohorts. We therefore set out to evaluate the incidence of risk for primary glaucoma and its subtypes in a Russian cohort of Mayak Production Association nuclear workers who received chronic radiation exposure over many years. Of these, we found a significantly increased relative risk (RR) of NTG incidence (RR = 1.88 95% confidence intervals (CI): 1.01, 3.51; p = 0.047) in workers exposed to gamma rays at cumulative brain absorbed dose above >1 Gy. We observed the linear relationship between NTG incidence and brain absorbed gamma dose with an excess relative risk per unit brain absorbed dose of 0.53 (95% CI: 0.01, 1.68; p < 0.05), but not for any other subtypes nor for total primary glaucoma. Such elevated risk of radiogenic NTG incidence, if confirmed in other cohorts, has significant implications for normal tissue complications in radiotherapy patients receiving ocular radiation exposure, and for ocular radiation protection in radiation workers.Entities:
Keywords: Mayak workers; high-tension glaucoma; ionizing radiation; normal-tension glaucoma; occupational chronic exposure; primary glaucoma
Year: 2022 PMID: 35158870 PMCID: PMC8833586 DOI: 10.3390/cancers14030602
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Characteristics of the study cohort.
|
| ||||||
|
|
|
|
| |||
|
|
|
|
|
|
| |
| <20 | 5399 | 32.4 | 771 | 13.5 | 6170 | 27.6 |
| 20–24 | 5863 | 35.1 | 2000 | 35.2 | 7863 | 35.1 |
| 25–29 | 2607 | 15.6 | 1108 | 19.5 | 3715 | 16.6 |
| 30–34 | 1103 | 6.6 | 632 | 11.1 | 1735 | 7.8 |
| 35–39 | 816 | 4.9 | 608 | 10.7 | 1424 | 6.4 |
| ≥40 | 900 | 5.4 | 570 | 10.0 | 1470 | 6.5 |
| Total | 16,688 | 100.0 | 5689 | 100.0 | 22,377 | 100.0 |
|
| ||||||
|
|
|
|
| |||
|
|
|
|
|
|
| |
| <50 | 20 | 5.5 | 4 | 2.3 | 24 | 4.4 |
| 50–59 | 77 | 20.9 | 9 | 5.2 | 86 | 15.9 |
| 60–69 | 165 | 45.0 | 60 | 34.7 | 225 | 41.7 |
| 70–79 | 88 | 24.0 | 74 | 42.8 | 162 | 30.0 |
| ≥80 | 17 | 4.6 | 26 | 15.0 | 43 | 8.0 |
| Total | 367 | 100.0 | 173 | 100.0 | 540 | 100.0 |
|
| ||||||
|
|
|
|
| |||
|
|
|
|
|
|
| |
| <50 | 17 | 5.6 | 4 | 2.7 | 21 | 4.7 |
| 50–59 | 64 | 21.3 | 7 | 4.8 | 71 | 15.8 |
| 60–69 | 127 | 42.2 | 52 | 35.4 | 179 | 40.0 |
| 70–79 | 79 | 26.3 | 61 | 41.5 | 140 | 31.2 |
| ≥80 | 14 | 4.6 | 23 | 15.6 | 37 | 8.3 |
| Total | 301 | 100.0 | 147 | 100.0 | 448 | 100.0 |
|
| ||||||
|
|
|
|
| |||
|
|
|
|
|
|
| |
| <50 | 3 | 4.5 | 0 | 0 | 3 | 3.3 |
| 50–59 | 13 | 19.7 | 2 | 7.7 | 15 | 16.3 |
| 60–69 | 38 | 57.7 | 8 | 30.8 | 46 | 50.0 |
| 70–79 | 9 | 13.6 | 13 | 50.0 | 22 | 23.9 |
| ≥80 | 3 | 4.5 | 3 | 11.5 | 6 | 6.5 |
| Total | 66 | 100.0 | 26 | 100.0 | 92 | 100.0 |
|
| ||||||
|
|
|
|
| |||
|
|
|
|
|
|
| |
| <50 | 1 | 6.7 | 2 | 11.8 | 3 | 9.4 |
| 50–59 | 4 | 26.7 | 4 | 23.5 | 8 | 25.0 |
| 60–69 | 5 | 33.3 | 5 | 29.4 | 10 | 31.3 |
| 70–79 | 5 | 33.3 | 6 | 35.3 | 11 | 34.3 |
| ≥80 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 100.0 | 17 | 100.0 | 32 | 100.0 |
|
| ||||||
|
|
|
|
| |||
|
|
|
|
|
|
| |
| <1 | 839 | 5.0 | 217 | 3.8 | 1056 | 4.7 |
| 1–9 | 6149 | 36.9 | 2012 | 35.4 | 8161 | 36.5 |
| ≥10 | 9700 | 58.1 | 3460 | 60.8 | 13,160 | 58.8 |
| Total | 16,688 | 100.0 | 5689 | 100.0 | 22,377 | 100.0 |
POAG, primary open-angle glaucoma; NTG, normal-tension glaucoma; HTG, high-tension glaucoma; PACG, primary angle-closure glaucoma.
Distribution of workers by brain absorbed dose from external exposure.
|
| ||||||
|
|
|
|
| |||
|
|
|
|
|
|
| |
| <0.25 | 8766 | 52.5 | 3457 | 60.8 | 12,223 | 54.6 |
| 0.25–0.5 | 2676 | 16.0 | 686 | 12.1 | 3362 | 15.0 |
| 0.5–1.0 | 2235 | 13.4 | 693 | 12.2 | 2928 | 13.1 |
| ≥1.0 | 3011 | 18.1 | 853 | 14.9 | 3864 | 17.37 |
| Total | 16,688 | 100.0 | 5689 | 100.0 | 22,377 | 100.0 |
|
| ||||||
|
|
|
|
| |||
|
|
|
|
|
|
| |
| 0 (unmeasured) | 13,213 | 79.2 | 5081 | 89.3 | 18,294 | 81.8 |
| <0.01 | 1456 | 8.7 | 316 | 5.6 | 1772 | 7.9 |
| 0.01–0.05 | 1310 | 7.9 | 218 | 3.8 | 1528 | 6.8 |
| ≥0.05 | 709 | 4.2 | 74 | 1.3 | 783 | 3.5 |
| Total | 16,688 | 100.0 | 5689 | 100.0 | 22,377 | 100.0 |
Relative risks of various types of primary glaucoma for different categories of cumulative brain absorbed dose of gamma-ray and neutron exposure lagged for 5 years.
| Cumulative Dose, Gy | Mean Dose, Gy | Number of Cases | RR (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| POAG | >HTG | NTG | PACG | POAG | HTG | NTG | PACG | ||
| RR in relation to the cumulative gamma-ray dose, Gy | |||||||||
| 0–0.25 | 0.14 | 270 | 233 | 37 | 17 | 1 | 1 | 1 | 1 |
| 0.25–0.5 | 0.41 | 82 | 69 | 13 | 4 | 0.92 | 0.90 | 1.07 | 1.05 |
| 0.5–0.75 | 0.68 | 37 | 33 | 4 | 5 | 0.77 | 0.82 | 0.53 | 2.46 |
| 0.75–1.00 | 0.93 | 42 | 33 | 9 | 2 | 1.14 | 1.08 | 1.59 | 0.89 |
| ≥1 | 1.19 | 108 | 79 | 29 | 4 | 1.15 | 1.02 | 1.88 | 0.85 |
| RR in relation to the cumulative neutron dose, Gy | |||||||||
| 0–0.001 | 0.0005 | 72 | 56 | 16 | 1 | 1 | 1 | 1 | 1 |
| 0.001–0.0025 | 0.002 | 24 | 19 | 5 | 1 | 0.88 | 0.94 | 0.70 | 0.88 |
| 0.0025–0.005 | 0.004 | 22 | 16 | 6 | 1 | 1.09 | 1.07 | 1.21 | 6.60 |
| 0.005–0.01 | 0.007 | 6 | 5 | 1 | 0 | 0.94 | 1.06 | 0.70 | – |
| ≥0.01 | 0.02 | 5 | 3 | 2 | 0 | 3.70 | 2.19 | 5.17 | – |
CI, confidence interval. Gy, gray. POAG, primary open-angle glaucoma. HTG, high-tension glaucoma. NTG, normal-tension glaucoma. PACG, primary angle-closure glaucoma. RR, relative risk. Estimates in bold are statistically significant.
Excess relative risks of various primary glaucoma type incidence in relation to cumulative brain absorbed dose of external gamma-ray and neutron exposure lagged for 5 years.
| Analysis | ERR/Gy (95%CI) | |||
|---|---|---|---|---|
| POAG | HTG | NTG | PACG | |
| Baseline analysis, | 0.07 (−0.08, 0.29) | −0.01 (−0.16, 0.20) | 0.53 (0.01, 1.68) | 0.04 (−0.51, 1.53) |
| Sensitivity analysis: dose lagging for | ||||
| 0 years | 0.07 (−0.08, 0.28) | −0.02 (−0.18, 0.18) | 0.54 (0.02, 1.70) | 0.04 (−0.50, 1.48) |
| 10 years | 0.07 (−0.08, 0.28) | −0.02 (−0.17, 0.19) | 0.53 (0.01, 1.66) | 0.06 (−0.51, 1.62) |
| 15 years | 0.07 (−0.08, 0.28) | −0.02 (−0.17, 0.19) | 0.53 (0.01, 1.67) | 0.02 (−0.51, 1.52) |
| 20 years | 0.06 (−0.09, 0.27) | −0.02 (−0.17, 0.19) | 0.48 (−0.02, 1.54) | −0.02 (−0.49, 1.22) |
| Sensitivity analysis: excluding from stratification | ||||
| Arterial hypertension | 0.08 (−0.07, 0.30) | −0.01 (−0.16, 0.19) | 0.61 (0.06, 1.81) | −0.006 (−0.48, 1.21) |
| Body mass index | 0.13 (−0.04, 0.35) | 0.02 (−0.13, 0.23) | 0.77 (0.14, 2.15) | −0.07 (−0.45, 0.90) |
| Diabetes mellitus | 0.09 (−0.06, 0.30) | 0.002 (−0.15, 0.21) | 0.54 (0.03, 1.65) | 0.03 (−0.50, 1.53) |
| Neutron dose | 0.06 (−0.08, 0.26) | −0.04 (−0.19, 0.15) | 0.65 (0.08, 1.85) | 0.08 (−0.51, 1.59) |
| Sensitivity analysis: including to stratification | ||||
| Smoking index | 0.09 (−0.07, 0.32) | −0.02 (−0.18, 0.19) | 0.74 (0.11, 2.13) | 0.19 (−0.54, 2.07) |
| Smoking and alcohol drinking habit | 0.16 (−0.03, 0.43) | 0.05 (−0.13, 0.32) | 0.72 (0.08, 2.23) | 0.22 (−0.40, 2.19) |
| Cataract | −0.02 (−0.14, 0.15) | −0.11 (−0.24, 0.05) | 0.50 (0.002, 1.59) | −0.03 (−0.48, 1.11) |
| Cataract surgery | 0.08 (−0.07, 0.30) | −0.002 (−0.16, 0.21) | 0.53 (0.008, 1.7) | 0.05 (−0.51, 1.59) |
| Sensitivity analysis: risk associated with neutron dose | ||||
| Baseline analysis, dose lagged for 5 years | 44.97 (−14.06, 132.1) | 29.3 (−22.65, 115.3) | 126.8 (−57.13, 488.8) | −5.37 (n/a, 519.0) |
CI, confidence interval; ERR/Gy, excess relative risk per unit absorbed dose; Gy, gray; n/a, not available; POAG, primary open-angle glaucoma; HTG, high-tension glaucoma; NTG, normal-tension glaucoma; PACG, primary angle-closure glaucoma; Estimates in bold are statistically significant.
Figure 1Normal-tension glaucoma incidence in relation to the cumulative brain absorbed gamma dose from external exposure lagged for 5 years.
Excess relative risks various primary glaucoma type incidence in relation to cumulative brain absorbed dose of external gamma-ray exposure lagged for 5 years—modification effects.
| Analysis | ERR/Gy (95%CI) | |||
|---|---|---|---|---|
| POAG | HTG | NTG | PACG | |
| Sensitivity analysis: the dataset restricted to certain groups of workers | ||||
| Sex | ||||
| Males | 0.06 (−0.11, 0.31) | −0.002 (−0.19, 0.26) | 0.31 (−0.20, 1.40) | 0.09 (−0.58, 3.07) |
| Females | 0.12 (−0.19, 0.59) | −0.04 (−0.33, 0.38) | 1.47 (0.007, 8.91) | −0.07 (n/a, 3.05) |
|
| ||||
| Attained age, years | ||||
| <50 | 0.12 (−0.70, 9.51) | 0.003 (−0.67, 7.40) | 11.97 (−14.56, 1382) | 25.73 (n/a, 41,300) |
| 50−59 | −0.04 (−0.45, 0.74) | −0.15 (n/a, 0.57) | 0.78 (−0.74, 13.09) | −0.18 (n/a, 1.16) |
| 60−69 | 0.14 (−0.09, 0.53) | 0.05 (−0.21, 0.47) | 0.41 (−0.20, 1.82) | −0.18 (n/a, −0.28) |
| ≥70 | 0.03 (−0.20, 0.36) | −0.03 (−0.25, 0.28) | 0.71 (−0.28, 5.49) | 3.2 (−3.13, 80.27) |
|
| ||||
|
| ||||
| Age at hire, years | ||||
| <30 | 0.02 (−0.12, 0.24) | −0.0 (−0.22, 0.15) | 0.40 (−0.06, 1.51) | 0.13 (−0.57, 2.83) |
| 30−39 | −0.20 (n/a, 0.38) | −0.15 (n/a, 0.80) | −0.20 (n/a. 0.45) | −0.20 (n/a, 19.31) |
| ≥40 | 7.85 (n/a, 73.89) | 5.14 (−3.28, 49.85) | 413,000 (n/a, 53,280,000) | −0.20 (n/a, 143.8) |
|
| ||||
1 p value in a test for heterogeneity between males and females, 2 p value in a test for heterogeneity among groups of workers by attained age based on the likelihood criteria, 3 p value in a test for non-linear trend in ERR/Gy by attained age based on likelihood criteria, 4 p value in a test for heterogeneity among group of workers by age at hire based on likelihood criteria; CI, confidence interval; ERR/Gy, excess relative risk per unit absorbed dose; Gy, gray; n/a, not available; POAG, primary open-angle glaucoma; HTG, high-tension glaucoma; NTG, normal-tension glaucoma; PACG, primary angle-closure glaucoma. Estimates in bold are statistically significant.